# US 2008/0287679 A1 · Process for preparing clopidogrel

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2008/0287679 A1
- Document ID: US20080287679A1
- Status: Published application
- Kind: A1
- Application number: 12/148,311
- Filed: 2008-04-18
- Published: 2008-11-20
- Earliest claimed: 2007-04-18
- Inventors: Vinod Kumar Kansal; Kompally Praveen; Dhirenkumar N. Mistry
- Web page: https://patentgrep.com/patent/US20080287679A1

## CPC

- C07D 495/04: Ortho-condensed systems
- A61P 7/02: Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
- A61P 9/00: Drugs for disorders of the cardiovascular system
- A61P 9/10: for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention encompasses processes for the preparation of optically pure clopidogrel camphorsulfonic acid salt without the need to isolate or recover (±) clopidogrel.

## Claims

### Claim 1

A process for preparing (−)-10-camphorsulphonic acid salt of methyl (+)-(S)-α-(2-chlorophenyl)-6,7-dihydrothieno[3,2-c]pyridine-5(4H)-acetate comprising: (a) reacting 4,5,6,7-tetrahydrothieno (3,2-c) pyridine hydrochloride with o-chlorophenyl-α-bromo methyl acetate in the presence of an acid acceptor to produce (±)-methyl α-(2-chlorophenyl)-6,7-dihydrothieno[3,2-c]pyridine-5(4H)-acetate; and (b) reacting in-situ (±)-methyl α-(2-chlorophenyl)-6,7-dihydrothieno[3,2-c]pyridine-5(4H)-acetate with (−)-10-camphorsulphonic acid to provide (−)-10-camphorsulphonic acid salt of methyl (+)-(S)-α-(2-chlorophenyl)-6,7-dihydrothieno[3,2-c]pyridine-5(4H)-acetate.

### Claim 2 (depends on 1)

The process of claim 1, wherein the acid acceptor is an inorganic base selected the group consisting of alkali metal carbonate and bicarbonate.

### Claim 3 (depends on 2)

The process of claim 2, wherein the acid acceptor is sodium carbonate, potassium carbonate, sodium bicarbonate or potassium bicarbonate.

### Claim 4 (depends on 1)

The process of claim 1, wherein the acid acceptor is employed in amounts ranging from about 1 mole to about 4 moles per one mole of 4,5,6,7-tetrahydrothieno-(3,2-c)pyridine hydrochloride.

### Claim 5 (depends on 1)

The process of claim 1, wherein the acid acceptor is employed in amounts ranging from about 1.5 moles to about 1.7 moles per one mole of 4,5,6,7-tetrahydrothieno-(3,2-c)pyridine hydrochloride.

### Claim 6 (depends on 1)

The process of claim 1, wherein the o-chlorophenyl-α-bromo methyl acetate is present in amounts ranging from about 0.8 moles to about 1.5 moles per one mole of 4,5,6,7-tetrahydrothieno (3,2-c) pyridine hydrochloride.

### Claim 7 (depends on 1)

The process of claim 1, wherein the reaction between 4,5,6,7-tetrahydrothieno (3,2-c) pyridine hydrochloride and o-chlorophenyl-α-bromo methyl acetate is carried out at a temperature of about 25° C. to about 100° C.

### Claim 8 (depends on 1)

The process of claim 1, wherein the reaction between 4,5,6,7-tetrahydrothieno (3,2-c) pyridine hydrochloride and o-chlorophenyl-α-bromo methyl acetate is carried out at a temperature of about 25° C. to about 60° C.

### Claim 9 (depends on 1)

The process of claim 1, wherein the reaction between 4,5,6,7-tetrahydrothieno (3,2-c) pyridine hydrochloride and o-chlorophenyl-α-bromo methyl acetate is carried out in a biphasic solvent system.

### Claim 10 (depends on 9)

The process of claim 9, wherein the biphasic solvent comprises water and water-immiscible organic solvent.

### Claim 11 (depends on 10)

The process of claim 10, wherein the water-immiscible organic solvent is selected from the group consisting of C6 to C12 aromatic hydrocarbons, halogenated hydrocarbons, C3 to C8 ketone, C3 to C10 alkyl ester, and mixtures thereof.

### Claim 12 (depends on 10)

The process of claim 10, wherein the water immiscible-organic solvent in the biphasic solvent is present in amounts ranging from about 2 ml to about 10 ml per gram of 4,5,6,7-tetrahydrothieno (3,2-c) pyridine hydrochloride.

### Claim 13 (depends on 9)

The process of claim 9, wherein the water is present in amounts ranging from about 0.5 volumes to about 5 ml per gram of 4,5,6,7-tetrahydrothieno (3,2-c) pyridine hydrochloride.

### Claim 14 (depends on 9)

The process of claim 9, wherein the biphasic solvent further comprises a co-solvent selected from the group consisting of dimethyl formamide, dimethyl sulfoxide, toluene, heptane and dimethylacetamide.

### Claim 15 (depends on 14)

The process of claim 14, wherein the co-solvent is present in amounts ranging from about 0.2 to about 1 ml per gram of 4,5,6,7-tetrahydrothieno (3,2-c) pyridine hydrochloride.

### Claim 16 (depends on 1)

The process of claim 1, wherein the reaction between 4,5,6,7-tetrahydrothieno (3,2-c) pyridine hydrochloride and o-chlorophenyl-α-bromo methyl acetate is carried out under phase transfer conditions.

### Claim 17 (depends on 16)

The process of claim 16, wherein the process further includes a phase transfer catalyst.

### Claim 18 (depends on 17)

The process of claim 17, wherein the phase transfer catalyst is selected from the group consisting of quaternary ammonium salts, phosphonium salts, crown ethers, and pyridium salt.

### Claim 19 (depends on 17)

The process of claim 17, wherein the phase transfer catalyst is a quaternary ammonium salt.

### Claim 20 (depends on 17)

The process of claim 17, wherein the phase transfer catalyst is employed in amounts ranging from about 0.01 mole to about 0.1 mole per one mole of 4,5,6,7-tetrahydrothieno-(3,2-c)pyridine hydrochloride.

### Claim 21 (depends on 1)

A process for preparing a pharmaceutically acceptable salt of (S)-clopiogrel, further comprising converting (−)-10-camphorsulphonic acid salt of methyl (+)-(S)-α-(2-chlorophenyl)-6,7-dihydrothieno[3,2-c]pyridine-5(4H)-acetate of claim 1 to a pharmaceutically acceptable salt of (S)-clopiogrel.

### Claim 22 (depends on 21)

The process of claim 21, wherein the pharmaceutically acceptable salt is bisulfate.

### Claim 23

A process for preparing (S)-clopidogrel (−)-10-camphorsulphonic acid salt comprising: (a) combining (R) clopidogrel or a mixture of (R) and (S) clopidogrel with a base to obtain a racemic mixture of (R) and (S) clopidogrel further enriched with (S) clopidogrel; and (b) reacting the racemic mixture of (R) and (S) clopidogrel further enriched with (S) clopidogrel with levorotatory camphorsulphonic acid, to provide (S)-clopidogrel (−)-10-camphorsulphonic acid salt, wherein steps (a) and (b) are carried out without an intermediate step of reacting the racemic mixture of (R) and (S) clopidogrel with sulfuric acid.

### Claim 24 (depends on 23)

The process of claim 23, further comprising recrystallizing (S)-clopidogrel (−)-10-camphorsulphonic acid salt in a suitable organic solvent.

### Claim 25 (depends on 23)

The process of claim 23, wherein the base is an organic amine, an alkali metal alkoxide, an alkali metal hydroxide, an alkaline earth metal hydroxide, an alkali metal hydride, an alkaline earth metal hydride, an alkali or alkaline earth metal carbonate or hydrogencarbonate salt.

### Claim 26 (depends on 23)

The process of claim 23, wherein the base is sodium hydroxide, potassium hydroxide, sodium C1 to C4 alkoxide or potassium C1 to C4 alkoxide.

### Claim 27 (depends on 23)

The process of claim 23, wherein the base is sodium t-butoxide or potassium t-butoxide.

### Claim 28 (depends on 23)

The process of claim 23, wherein the base is present in amounts ranging from about 0.01 to about 0.5 mole per one mole of (R) clopidogrel or a mixture of (R) and (S) clopidogrel.

### Claim 29 (depends on 23)

The process of claim 23, wherein prior to step (a), the process comprises combining a mother liquor of (R) clopidogrel (−)-10-camphorsulphonic acid salt or a mixture of (R) and (S) clopidogrel (−)-10-camphorsulphonic acid salt with a base in an organic solvent to obtain (R) clopidogrel or a mixture of (R) and (S) clopidogrel.

### Claim 30 (depends on 29)

The process of claim 29, wherein the base is an organic amine, an alkali metal alkoxide, an alkali metal hydroxide, an alkaline earth metal hydroxide, an alkali metal hydride, an alkaline earth metal hydride, an alkali or alkaline earth metal carbonate or hydrogencarbonate salt.

### Claim 31 (depends on 29)

The process of claim 29, wherein the base is sodium hydrogen carbonate.

### Claim 32 (depends on 29)

The process of claim 29, wherein the base is employed in amounts ranging from about 0.1 to 1.0 mole per 1 liter of mother liquor.

### Claim 33 (depends on 29)

The process of claim 29, wherein the organic solvent is selected from the group consisting of C6 to C12 aromatic hydrocarbons, halogenated hydrocarbons, C3 to C8 ketone, C3 to C10 alkyl ester, and mixtures thereof.

### Claim 34 (depends on 23)

The process of claim 23, wherein the process further comprises converting (S)-clopidogrel (−)-10-camphorsulphonic acid salt to a pharmaceutically acceptable salt of (S)-clopiogrel.

### Claim 35 (depends on 34)

The process of claim 34, wherein the pharmaceutically acceptable salt is bisulfate.

### Claim 36

A process for preparing clopidogrel camphosulfonate comprising combining 4,5,6,7-tetrahydrothieno-(3,2-c)pyridine hydrochloride, toluene, dimethyl formamide, o-chlorophenyl-α-bromo methyl acetate to obtain a reaction mixture containing (±) clopidogrel; and converting (±) clopidogrel to clopidogrel camphosulfonate without the recovery of (±) clopidogrel.

### Claim 37 (depends on 36)

The process of claim 36, wherein the process further comprises adding tetrabutylammonium hydrogen sulphate and/or a base to the combination of 4,5,6,7-tetrahydrothieno-(3,2-c)pyridine hydrochloride, toluene, dimethyl formamide, and o-chlorophenyl-α-bromo methyl acetate.

### Claim 38 (depends on 36)

A process for preparing a pharmaceutically acceptable salt of (S)-clopiogrel, further comprising converting the (−)-10-camphorsulphonic acid salt of methyl (+)-(S)-α-(2-chlorophenyl)-6,7-dihydrothieno[3,2-c]pyridine-5(4H)-acetate of claim 36 to a pharmaceutically acceptable salt of (S)-clopiogrel.

### Claim 39

A process for preparing (S)-clopidogrel bisulfate comprising:
(a) reacting 4,5,6,7-tetrahydrothieno (3,2-c) pyridine hydrochloride with o-chlorophenyl-α-bromo methyl acetate in the presence of an acid acceptor to produce (±)-methyl α-(2-chlorophenyl)-6,7-dihydrothieno[3,2-c]pyridine-5(4H)-acetate;
(b) reacting in-situ (±)-methyl α-(2-chlorophenyl)-6,7-dihydrothieno[3,2-c]pyridine-5(4H)-acetate with (−)-10-camphorsulphonic acid to provide (−)-10-camphorsulphonic acid salt of methyl (+)-(S)-α-(2-chlorophenyl)-6,7-dihydrothieno[3,2-c]pyridine-5(4H)-acetate, wherein the camphorsulfonate precipitates out of reaction mixture leaving (R)-clopidogrel in the reaction mixture (mother liquor), optionally in a mixture with lesser amounts of (S)-clopidogrel;
(c) combining the (R) clopidogrel or the mixture of (R) and (S) clopidogrel remaining in the reaction mixture (mother liquor) with a base to obtain a racemic mixture of (R) and (S) clopidogrel further enriched with (S) clopidogrel;
(d) reacting the racemic mixture of (R) and (S) clopidogrel further enriched with (S) clopidogrel with levorotatory camphorsulphonic acid, to provide (S)-clopidogrel (−)-10-camphorsulphonic acid salt, wherein steps (c) and (d) are carried out without an intermediate step of reacting the racemic mixture of (R) and (S) clopidogrel with sulfuric acid; and
(e) converting (S)-clopidogrel (−)-10-camphorsulphonic acid salt to (S)-clopidogrel bisulfate.
